Non-metastatic castration-resistant prostate cancer

Non-metastatic castration-resistant prostate cancer is an advanced clinical state of prostate adenocarcinoma characterized by disease progression despite medical or surgical castration It affects men undergoing continuous androgen deprivation therapy who demonstrate biochemical progression, evidenced by sequentially rising prostate-specific antigen levels despite maintaining castrate serum testosterone levels (<50 ng/dL)

Non-metastatic castration-resistant prostate cancer is an advanced clinical state of prostate adenocarcinoma characterized by disease progression despite medical or surgical castration It affects men undergoing continuous androgen deprivation therapy who demonstrate biochemical progression, evidenced by sequentially rising prostate-specific antigen levels despite maintaining castrate serum testosterone levels (<50 ng/dL) Pathophysiologically driven by persistent androgen receptor axis signaling ...

It affects men undergoing continuous androgen deprivation therapy who demonstrate biochemical progression, evidenced by sequentially rising prostate-specific antigen levels despite maintaining castrate serum testosterone levels (<50 ng/dL) Pathophysiologically driven by persistent androgen receptor axis signaling and adaptation, this entity is clinically defined by the absence of detectable distant metastases on conventional imaging modalities, such as computed tomography and technetium bone sca...

Pathophysiologically driven by persistent androgen receptor axis signaling and adaptation, this entity is clinically defined by the absence of detectable distant metastases on conventional imaging modalities, such as computed tomography and technetium bone scans Patients in this state are typically asymptomatic but face an elevated risk of progressing to overt metastatic dissemination and cancer-related mortality

Patients in this state are typically asymptomatic but face an elevated risk of progressing to overt metastatic dissemination and cancer-related mortality

Patients in this state are typically asymptomatic but face an elevated risk of progressing to overt metastatic dissemination and cancer-related mortality